Globeimmune Inc
OTC:GBIM

Watchlist Manager
Globeimmune Inc Logo
Globeimmune Inc
OTC:GBIM
Watchlist
Price: 0.0001 USD
Market Cap: $575

Operating Margin

-33.3%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-33.3%
=
Operating Income
$-2.1m
/
Revenue
$6.2m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-33.3%
=
Operating Income
$-2.1m
/
Revenue
$6.2m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Globeimmune Inc
OTC:GBIM
575.2 USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
173.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 80% of companies in the United States of America
Percentile
20th
Based on 14 112 companies
20th percentile
-33.3%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Globeimmune Inc
Glance View

Market Cap
575 USD
Industry
Biotechnology

GlobeImmune, Inc. is a biopharmaceutical company. The company is headquartered in Louisville, Colorado. The company went IPO on 2014-07-02. The firm is engaged in development of products for the treatment of cancer and infectious diseases. The firm provides Tarmogen platform, which activate the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells, in contrast to traditional vaccines which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. The firm's oncology product candidates include GI-6301, GI-6207 and GI-4000. The firm's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.

GBIM Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-33.3%
=
Operating Income
$-2.1m
/
Revenue
$6.2m
How has Operating Margin changed over time?

Over the last 3 years, Globeimmune Inc’s Operating Margin has increased from -65% to -33.3%. During this period, it reached a low of -204.8% on Jun 30, 2015 and a high of 39.1% on Mar 31, 2014.

Back to Top